Siemens Healthineers AG/ADR (SMMNY)
Siemens Healthineers AG (SMMNY), operating through its various subsidiaries, is a global enterprise that provides a comprehensive suite of diagnostic and therapeutic medical products and services. These offerings are extended to healthcare professionals and institutions across numerous international markets, including Germany, the United States, the broader European continent, the CIS region, Africa, the Middle East, the Americas, the Asia Pacific region, Japan, and China. The company's business is structured across four primary divisions: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment supplies cutting-edge systems such as magnetic resonance imaging (MRI), computed tomography (CT), X-ray, molecular imaging, and ultrasound technologies. It also develops sophisticated software solutions designed to streamline the interpretation and structured reporting of diagnostic images from diverse modalities. The Diagnostics segment delivers in-vitro diagnostic products and associated services, catering to healthcare providers in both general and specialized laboratory settings, as well as point-of-care diagnostics. This division further offers workflow solutions to optimize laboratory operations and provides advanced informatics products. The Varian segment specializes in oncology solutions, featuring advanced technologies like microwave, cryoablation, and embolization. It also furnishes extensive clinical professional services and tailored support programs to assist oncology departments in hospitals and clinics with their cancer care operations. The Advanced Therapies segment focuses on developing products that facilitate image-guided, minimally invasive clinical procedures. These solutions are applied across various medical specialties, including cardiology, neurology, and oncology. Its portfolio includes angiography systems, mobile C-arms, and AI-powered clinical applications that enhance procedural precision. Beyond its core product lines, Siemens Healthineers AG offers a broad range of essential technical customer services. These include maintenance and repair, provision of spare parts, medical equipment performance management, training programs, clinical education, e-learning resources, planning and design assistance, financing options, asset management, and managed departmental services for laboratories and other healthcare facilities. The company also provides healthcare consulting, products, and additional services. Established in 1896, Siemens Healthineers AG maintains its corporate headquarters in Forchheim, Germany, and functions as a subsidiary of Siemens Aktiengesellschaft.
Industry: Medical - Devices
Siemens Healthineers AG
No splits on record
Nothing in SMMNY's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 | 2015-09-30 |
| Revenue | $24.65B | $25.02B | $24.26B | $24.29B | $20.14B | $16.18B | $16.24B | $15.02B | $15.3B | $15.16B | $14.47B |
| YoY Growth | -1.5% | 3.2% | -0.2% | 20.7% | 24.5% | -0.4% | 8.1% | -1.8% | 1.0% | 4.7% | - |
| Cost of Revenue | $15.13B | $15.55B | $15.63B | $15.19B | $12.36B | $9.93B | $9.76B | $8.91B | $8.93B | $9.04B | $8.8B |
| Gross Profit | $9.52B | $9.47B | $8.62B | $9.1B | $7.78B | $6.24B | $6.48B | $6.12B | $6.37B | $6.12B | $5.67B |
| Gross Margin | 38.6% | 37.9% | 35.6% | 37.5% | 38.6% | 38.6% | 39.9% | 40.7% | 41.6% | 40.4% | 39.2% |
| Research and Development | $2.07B | $2.15B | $2.09B | $2B | $1.73B | $1.5B | $1.49B | $1.43B | $1.4B | $1.28B | $1.18B |
| Selling, General, and Administrative | $3.84B | $3.64B | $3.81B | $3.68B | $2.94B | $2.46B | $2.41B | $2.41B | $2.49B | $2.47B | $2.36B |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $5.9B | $5.78B | $5.89B | $5.68B | $4.67B | $3.96B | $3.9B | $3.84B | $3.89B | $3.75B | $3.54B |
| Operating Income (EBIT) | $3.62B | $3.69B | $2.73B | $3.43B | $3.11B | $2.28B | $2.59B | $2.28B | $2.48B | $2.37B | $2.13B |
| Operating Margin | 14.7% | 14.8% | 11.3% | 14.1% | 15.4% | 14.1% | 15.9% | 15.1% | 16.2% | 15.6% | 14.7% |
| Interest Expense | $448.19M | $532.55M | $331.16M | $132.02M | $92.86M | $85.03M | $137.61M | $229.35M | $298.72M | $241.66M | $130.9M |
| Interest Income | $104.4M | $133.14M | $95.1M | $53.7M | $36.92M | $59.3M | $42.51M | $45.87M | $13.43M | $15.66M | $21.26M |
| Other Income (Expense) | -$614.22M | -$869.31M | -$572.83M | -$295.36M | -$417.31M | -$96.22M | -$133.14M | -$262.92M | -$271.87M | -$221.52M | -$32.45M |
| Income Before Tax (EBT) | $3.01B | $2.82B | $2.16B | $3.13B | $2.69B | $2.19B | $2.45B | $2.01B | $2.21B | $2.15B | $2.1B |
| Income Tax Expense | $722.37M | $631M | $450.88M | $834.62M | $736.17M | $594.08M | $679.11M | $576.18M | $650.02M | $660.09M | $653.38M |
| Net Income | $2.26B | $2.17B | $1.69B | $2.28B | $1.93B | $1.58B | $1.75B | $1.42B | $1.54B | $1.47B | $1.43B |
| Net Income Margin | 9.2% | 8.7% | 7.0% | 9.4% | 9.6% | 9.8% | 10.8% | 9.4% | 10.1% | 9.7% | 9.9% |
| Supplementary Data | |||||||||||
| EPS | 0.90 | 0.87 | 0.68 | 0.91 | 0.79 | 0.71 | 0.79 | 0.64 | 0.69 | 0.66 | 0.64 |
| Diluted EPS | 0.90 | 0.87 | 0.67 | 0.91 | 0.78 | 0.71 | 0.79 | 0.63 | 0.69 | 0.66 | 0.64 |
| Weighted Average OS | 2.24B | 2.23B | 2.24B | 2.25B | 2.20B | 2.00B | 2.00B | 2.00B | 2.00B | 2.00B | 2.00B |
| EBITDA | $4.83B | $4.73B | $4.23B | $4.76B | $3.94B | $3.18B | $3.28B | $2.83B | $3.14B | $3.04B | $2.85B |
| EBITDA Margin | 19.6% | 18.9% | 17.4% | 19.6% | 19.6% | 19.7% | 20.2% | 18.8% | 20.5% | 20.1% | 19.7% |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 | 2015-09-30 |
| Assets | |||||||||||
| Current Assets | |||||||||||
| Cash and Cash Equivalents | $2.43B | $3B | $1.84B | $1.61B | $1.48B | $733.93M | $1.03B | $580.66M | $205.86M | $230.47M | $81.67M |
| Short-Term Investments | $81.67M | $0 | $0 | $0 | $0 | $0 | $0 | $30.21M | $12.31M | $19.02M | $41.4M |
| Cash and Short-Term Investments | $2.52B | $3B | $1.84B | $1.61B | $1.48B | $733.93M | $1.03B | $610.86M | $218.17M | $249.49M | $123.07M |
| Accounts Receivable | $9.55B | $8.06B | $8.37B | $7.9B | $6.73B | $7.92B | $5.23B | $5.31B | $6.62B | $7.09B | $6.86B |
| Inventory | $4.57B | $4.68B | $4.8B | $4.49B | $3.56B | $2.58B | $2.31B | $2.05B | $1.8B | $1.46B | $1.41B |
| Other Current Assets | $1.63B | $219.28M | $570.59M | $764.14M | $148.8M | $158.87M | $70.48M | $38.04M | $38.04M | $11.19M | $12.31M |
| Total Current Assets | $18.53B | $16.16B | $15.82B | $14.97B | $12.06B | $11.49B | $8.7B | $8.05B | $8.72B | $8.86B | $8.45B |
| Long-Term Assets | |||||||||||
| Property, Plant & Equipment Net | $5.28B | $5.01B | $4.71B | $4.78B | $4.15B | $3.1B | $2.59B | $2.15B | $1.75B | $1.71B | $1.46B |
| Goodwill | $22.51B | $19.76B | $20.27B | $21.33B | $19.53B | $10.11B | $9.61B | $9.15B | $8.94B | $9.29B | $9.26B |
| Intangible Assets | $8.55B | $7.9B | $8.64B | $9.75B | $9.03B | $2.14B | $1.76B | $1.76B | $1.71B | $1.77B | $1.79B |
| Long-Term Investments | $1.28B | $1.57B | $1.79B | $2.92B | $1.08B | $435.21M | $428.5M | $236.07M | $1.75B | $209.22M | $205.86M |
| Deferred Tax Assets | $538.98M | $532.55M | $465.42M | $643.31M | $538.14M | $468.78M | $516.89M | $440.81M | $456.47M | $586.25M | $334.52M |
| Other Long-Term Assets | $2.17B | $594.08M | $537.02M | $498.98M | $514.65M | $328.93M | $359.13M | $322.21M | $299.84M | $281.94M | $272.99M |
| Total Long-Term Assets | $39.8B | $35.37B | $36.41B | $39.92B | $34.85B | $16.59B | $15.27B | $14.05B | $14.9B | $13.84B | $13.32B |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $58.33B | $51.53B | $52.23B | $54.88B | $46.91B | $28.08B | $23.97B | $22.11B | $23.62B | $22.71B | $21.77B |
| Liabilities | |||||||||||
| Current Liabilities | |||||||||||
| Accounts Payable | $3.02B | $2.38B | $2.46B | $2.59B | $2.15B | $1.52B | $1.57B | $1.43B | $1.25B | $1.11B | $1.05B |
| Short-Term Debt | $4.89B | $3.08B | $4.92B | $3.18B | $2.41B | $2.47B | $491.15M | $770.85M | $6.53B | $4.6B | $9.5B |
| Current Income Tax Payable | $1.23B | $437.45M | $949.86M | $1.07B | $845.81M | $642.19M | $601.91M | $459.83M | $136.49M | $125.31M | $153.28M |
| Current Unearned Revenue | $4.79B | $4.06B | $4.06B | $4.19B | $3.25B | $2B | $1.95B | $1.71B | $1.57B | $616.46M | $594.08M |
| Other Current Liabilities | $7.63B | $1.38B | $1.47B | $1.38B | $1.29B | $788.75M | $871.55M | $817.84M | $818.96M | $3.02B | $3.09B |
| Total Current Liabilities | $16.62B | $12.95B | $15.04B | $13.45B | $11.31B | $8.15B | $6.27B | $5.93B | $11.31B | $10.41B | $15.27B |
| Long-Term Liabilities | |||||||||||
| Long-Term Debt | $14.25B | $14.46B | $13.21B | $14.93B | $13.07B | $3.33B | $4.55B | $4.48B | $5.78B | $6.14B | $14.54M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $253.97M | $255.09M | $253.97M | $493.39M | $421.79M |
| Long-Term Deferred Tax Liabilities | $1.51B | $1.69B | $1.86B | $2.36B | $2.33B | $525.84M | $419.55M | $389.34M | $289.77M | $220.4M | $177.89M |
| Other Long-Term Liabilities | $1.5B | $1.42B | $1.33B | $1.41B | $1.69B | $1.71B | $1.51B | $1.32B | $2.29B | $2.74B | $1.7B |
| Total Long-Term Liabilities | $17.92B | $18.16B | $16.91B | $19.22B | $17.63B | $5.92B | $6.76B | $6.47B | $8.63B | $9.6B | $2.33B |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $34.55B | $31.11B | $31.94B | $32.67B | $28.95B | $14.08B | $13.03B | $12.4B | $19.94B | $20.01B | $17.6B |
| Stockholders' Equity | |||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $1.48B | $1.26B | $1.26B | $1.26B | $1.26B | $1.2B | $1.12B | $1.12B | $0 | $3.51B | $4.91B |
| Retained Earnings | $4.26B | $2.41B | $1.55B | $1B | -$335.64M | -$1.43B | -$2.08B | -$3.38B | $4.53B | $0 | $0 |
| Comprehensive Income & Other | -$2.2B | -$584.01M | $380.39M | $2.64B | -$412.84M | -$829.03M | -$166.7M | $11.95B | -$854.76M | -$858.12M | -$778.68M |
| Other Stockholders' Equity | $17.97B | $16.69B | $17.42B | $19.93B | $17.02B | $14.21B | $11.89B | $11.94B | -$854.76M | -$858.12M | -$778.68M |
| Total Equity | $23.72B | $20.36B | $20.23B | $22.19B | $17.94B | $13.98B | $10.93B | $9.68B | $3.67B | $2.66B | $4.13B |
| Minority Interest | $67.04M | $54.82M | $58.18M | $17.9M | $20.14M | $14.54M | $14.54M | $22.38M | $8.95M | $36.92M | $43.63M |
| Total Liabilities and Equity | $58.26B | $51.47B | $52.17B | $54.87B | $46.89B | $28.06B | $23.96B | $22.08B | $23.61B | $22.67B | $21.72B |
| Supplementary Data | |||||||||||
| Total Debt | $19.8B | $18.13B | $18.63B | $18.63B | $16.02B | $6.16B | $5.07B | $5.27B | $12.32B | $10.76B | $9.53B |
| Net Debt | -$1.59B | $15.13B | $16.79B | $17.02B | $14.54B | $5.42B | $4.04B | $4.69B | $12.12B | $10.53B | $9.45B |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 | 2015-09-30 |
| Operating Activities | |||||||||||
| Net Income | $2.26B | $2.17B | $1.69B | $2.28B | $1.93B | $1.58B | $1.75B | $1.42B | $1.54B | $1.47B | $1.43B |
| Depreciation & Amortization | $1.37B | $1.37B | $1.74B | $1.5B | $1.16B | $911.82M | $693.66M | $592.96M | $639.95M | $661.21M | $629.88M |
| Deferred Income Tax | -$317.74M | -$228.24M | -$296.48M | -$297.6M | -$97.34M | $43.63M | $7.83M | $55.94M | $15.66M | $0 | $0 |
| Stock-Based Compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Changes in Working Capital: | |||||||||||
| Accounts Receivable | -$431.86M | -$472.13M | -$864.83M | -$547.09M | -$803.3M | $59.3M | -$542.62M | -$327.81M | -$190.2M | $0 | $0 |
| Inventory | -$80.55M | $43.63M | -$506.82M | -$538.14M | -$24.61M | -$371.44M | -$138.73M | -$217.05M | -$96.22M | $0 | $0 |
| Accounts Payable | $241.49M | -$69.37M | -$22.38M | $276.34M | $355.78M | $1.12M | $100.69M | $187.96M | $186.84M | $0 | $0 |
| Other Working Capital | -$341.23M | -$179.01M | $452M | -$449.76M | $531.43M | -$236.07M | -$343.47M | -$403.89M | -$247.25M | -$212.57M | $91.74M |
| Total Working Capital Change | -$613.1M | -$676.87M | -$942.03M | -$1.26B | $59.3M | -$547.09M | -$924.13M | -$760.78M | -$346.83M | -$212.57M | -$120.83M |
| Other Non-Cash Items | $553.81M | $126.42M | -$167.82M | $298.72M | $55.94M | $32.45M | $145.44M | $307.67M | $78.32M | -$46.99M | $92.86M |
| Net Cash from Operating | $3.25B | $2.76B | $2.02B | $2.52B | $3.11B | $2.02B | $1.68B | $1.61B | $1.93B | $1.87B | $2.03B |
| Investing Activities | |||||||||||
| Capital Expenditures | -$862.59M | -$778.68M | -$937.55M | -$953.22M | -$754.07M | -$623.17M | -$647.79M | -$592.96M | -$521.36M | -$474.37M | -$398.29M |
| Acquisitions | -$90.62M | $38.04M | -$250.61M | -$15.66M | -$15.05B | -$1.51B | -$86.15M | -$236.07M | $14.54M | -$8.95M | $412.84M |
| Purchases of Investments | -$2.24M | -$4.48M | -$7.83M | -$2.24M | -$13.43M | -$6.71M | -$6.71M | -$2.24M | $0 | -$4.48M | -$2.24M |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$955.46M | -$745.12M | -$1.2B | -$971.12M | -$15.82B | -$2.14B | -$740.65M | -$831.27M | -$506.82M | -$487.8M | $12.31M |
| Financing Activities | |||||||||||
| Debt Repaid | $138.73M | $241.66M | $212.57M | $166.7M | $154.39M | - | - | - | - | - | - |
| Common Stock Issuance | $0 | $0 | $20.14M | $1.12M | $2.59B | $3.03B | $0 | $0 | $0 | $0 | $0 |
| Common Stock Repurchases | -$317.74M | -$11.19M | -$471.01M | -$345.71M | -$285.29M | -$74.96M | -$58.18M | -$62.65M | $0 | $0 | $0 |
| Dividends Paid | -$1.12B | -$1.19B | -$1.19B | -$1.07B | -$957.69M | -$892.8M | -$782.04M | -$257.32M | -$393.82M | -$421.79M | -$165.58M |
| Other Financing Activities | -$25.73M | -$17.9M | -$16.78M | -$21.26M | $12.24B | -$17.9M | -$16.78M | -$10.07M | -$3.36M | -$833.51M | -$1.8B |
| Net Cash from Financing | -$2.73B | -$1.45B | -$425.14M | -$1.56B | $13.41B | -$140.97M | -$524.72M | -$373.68M | -$1.43B | -$1.23B | -$1.98B |
| Forex Effect | $15.39M | $601.91M | -$172.3M | $136.49M | $38.04M | -$34.68M | $38.04M | -$31.33M | -$13.43M | -$1.12M | $15.66M |
| Net Change in Cash | -$419.55M | $1.16B | $230.47M | $127.54M | $745.12M | -$295.36M | $448.64M | $374.8M | -$24.61M | $148.8M | $81.67M |
| Supplementary Data | |||||||||||
| Operating Cash Flow | $3.25B | $2.76B | $2.02B | $2.52B | $3.11B | $2.02B | $1.68B | $1.61B | $1.93B | $1.87B | $2.03B |
| Capital Expenditure | -$862.59M | -$778.68M | -$937.55M | -$953.22M | -$754.07M | -$623.17M | -$647.79M | -$592.96M | -$521.36M | -$474.37M | -$398.29M |
| Free Cash Flow | $2.39B | $1.98B | $1.09B | $1.57B | $2.36B | $1.4B | $1.03B | $1.02B | $1.41B | $1.39B | $1.63B |
| Cash at Beginning | $2.86B | $1.84B | $1.61B | $1.48B | $733.93M | $1.03B | $580.66M | $205.86M | $230.47M | $81.67M | $0 |
| Cash at End | $2.44B | $3B | $1.84B | $1.61B | $1.48B | $733.93M | $1.03B | $580.66M | $205.86M | $230.47M | $81.67M |